- Trisk Bio and NanoMosaic have partnered to integrate the Tessie analytics platform into AAV process development, quality control, and release testing workflows.
- Trisk implemented the platform ahead of the FDA CBER’s January 2026 Advanced Manufacturing Technology designation for AAV analytics.
Trisk Bio Ltd and NanoMosaic have entered into a partnership to integrate the Tessie analytics platform across Trisk’s AAV process development, quality control, and release testing operations.
According to the companies, the collaboration is intended to strengthen analytical capabilities for AAV manufacturing and support regulatory readiness for cell and gene therapy developers. Trisk said it adopted the Tessie platform before the FDA Center for Biologics Evaluation and Research granted Advanced Manufacturing Technology designation to the technology in January 2026.
The companies stated that the Tessie platform is designed to improve direct measurement of critical quality attributes in AAV analytics. Trisk said the technology will be used throughout its development and manufacturing workflows to support more accurate analytical assessment during process development and product release activities.
“We are pleased to see the FDA validate the advantages that have been clear to us from our first engagements with NanoMosaic. Legacy AAV analytics can misread critical quality attributes by orders of magnitude.”
Gaurav Venkataraman, CEO of Trisk Bio
NanoMosaic stated that the agreement expands the use of its analytical technology within the AAV contract development and manufacturing sector. Trisk added that the partnership aligns with its CDMO and contract manufacturing strategy focused on supporting developers with manufacturing and analytical services for cell and gene therapy programs.
